Active Substance & Generic Molecule Directory

Sitagliptin Phosphate Monohydrate in Malaysia: Registered Brands, Dosages & Price Comparison

Directory of all approved pharmaceutical brands containing Sitagliptin Phosphate Monohydrate registered with the National Pharmaceutical Regulatory Agency (NPRA) / Ministry of Health Malaysia (KKM).

13
Registered Brands
Availability in Malaysia:13 Prescription (MAL-A)
Showing 13 of 13 registered brands
MAL Reg NoBrand Formulation NameStrength / DosageClassificationRegistration HolderAction
MAL22046028AZFORTESIA FILM COATED TABLET 100MG128.50 mgPrescription (MAL-A)DUOPHARMA MANUFACTURING (BANGI) SDN. BHD.Compare →
MAL17117034AEhovid-Sitagliptin Tablet 100mg128.50mgPrescription (MAL-A)HOVID BERHADCompare →
MAL25036156AZJIMANDIN 100MG FILM COATED TABLETS128.5 mgPrescription (MAL-A)KOMEDIC SDN BHDCompare →
MAL25036154AZJIMANDIN 25MG FILM COATED TABLETS32.125 mgPrescription (MAL-A)KOMEDIC SDN BHDCompare →
MAL25036155AZJIMANDIN 50MG FILM COATED TABLETS64.25 mgPrescription (MAL-A)KOMEDIC SDN BHDCompare →
MAL22126054AZSitavio 100mg Film Coated Tablets128.500 mgPrescription (MAL-A)NOVUGEN PHARMA SDN. BHD.Compare →
MAL26066014AESitavio 25mg Film Coated Tablets32.13 mgPrescription (MAL-A)NOVUGEN PHARMA SDN. BHD.Compare →
MAL22126053AZSitavio 50mg Film Coated Tablets64.250 mgPrescription (MAL-A)NOVUGEN PHARMA SDN. BHD.Compare →
MAL24096050AZSitavio-M 50mg/1000mg Film Coated Tablets64.250 mgPrescription (MAL-A)NOVUGEN PHARMA SDN. BHD.Compare →
MAL24096057AZSitavio-M 50mg/500mg Film Coated Tablets64.250 mgPrescription (MAL-A)NOVUGEN PHARMA SDN. BHD.Compare →
MAL24096056AZSitavio-M 50mg/850mg Film Coated Tablets64.250 mgPrescription (MAL-A)NOVUGEN PHARMA SDN. BHD.Compare →
MAL26036024AZSTAGEO FILM-COATED TABLETS 100MG128.50 mgPrescription (MAL-A)XEPA-SOUL PATTINSON (MALAYSIA) SDN. BHD.Compare →
MAL21086014AZXigatin Film Coated Tablet 100mg128.5 mgPrescription (MAL-A)Y.S.P. INDUSTRIES (M) SDN. BHD.Compare →

Generic Bioequivalence & Drug Substitution in Malaysia

Generic medications registered under NPRA contain the identical active pharmaceutical ingredient (API) in identical dosage strength and route of administration as the originator brand. NPRA requires rigorous bioequivalence (BE) studies demonstrating that generic drugs deliver the exact therapeutic effect. Always confirm with your doctor or community pharmacist before switching between prescription brands.